Article content material

VANCOUVER, British Columbia, Feb. 28, 2023 (GLOBE NEWSWIRE) — Algernon Prescription drugs Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Firm” or “Algernon”) a scientific stage pharmaceutical improvement firm publicizes that efficient on the opening of markets on March 3, 2023, the Class A Widespread Shares (the “Widespread Shares”) of the Firm will start buying and selling following a four-for-one ahead share cut up (the “Ahead Cut up”), through which three (3) further Widespread Shares shall be issued for each one (1) Widespread Share at present excellent. The Firm at present has 2,413,431 issued and excellent Widespread Shares. Upon completion of the Ahead Cut up, the Firm could have roughly 9,653,724 Widespread Shares excellent. The aim of the Ahead Cut up is to extend liquidity of the Widespread Shares.

Article content material

The Ahead Cut up is being performed on a “push-out” foundation and subsequently the Firm’s CUSIP quantity will stay the identical. DRS statements for the extra shares ensuing from the Ahead Cut up shall be mailed to shareholders of report as of March 6, 2023 by the Firm’s switch agent, TMX Belief Firm. Shareholders of the Firm don’t must take any motion with respect to the Ahead Cut up.

Article content material

About Algernon Prescription drugs Inc. 

Algernon Prescription drugs is a Canadian scientific stage drug improvement and repurposing firm investigating a number of medicine for unmet international medical wants. Algernon Prescription drugs has lively analysis packages for IPF with persistent cough, and persistent kidney illness, and is the guardian firm of a newly created non-public subsidiary known as Algernon NeuroScience, that’s advancing a psychedelic program investigating a proprietary type of psychedelic DMT for stroke and traumatic mind harm.

Article content material

CONTACT INFORMATION

Christopher J. Moreau
CEO
Algernon Prescription drugs Inc.
604.398.4175 ext 701
information@algernonpharmaceuticals.com
traders@algernonpharmaceuticals.com
www.algernonpharmaceuticals.com.

Neither the Canadian Securities Change nor its Market Regulator (as that time period is outlined within the insurance policies of the Canadian Securities Change) accepts duty for the adequacy or accuracy of this launch.

CAUTIONARY DISCLAIMER STATEMENT: No Securities Change has reviewed nor accepts duty for the adequacy or accuracy of the content material of this information launch. This information launch comprises forward-looking statements referring to product improvement, licensing, commercialization and regulatory compliance points and different statements that aren’t historic information. Ahead-looking statements are sometimes recognized by phrases equivalent to “will”, “could”, “ought to”, “anticipate”, “expects” and comparable expressions. All statements apart from statements of historic reality, included on this launch are forward-looking statements that contain dangers and uncertainties. There will be no assurance that such statements will show to be correct and precise outcomes and future occasions may differ materially from these anticipated in such statements. Necessary components that would trigger precise outcomes to vary materially from the Firm’s expectations embody the failure to fulfill the circumstances of the related securities change(s) and different dangers detailed on occasion within the filings made by the Firm with securities rules. The reader is cautioned that assumptions used within the preparation of any forward-looking info could show to be incorrect. Occasions or circumstances could trigger precise outcomes to vary materially from these predicted, because of quite a few recognized and unknown dangers, uncertainties, and different components, lots of that are past the management of the Firm. The reader is cautioned to not place undue reliance on any forward-looking info. Such info, though thought-about affordable by administration on the time of preparation, could show to be incorrect and precise outcomes could differ materially from these anticipated. Ahead-looking statements contained on this information launch are expressly certified by this cautionary assertion. The forward-looking statements contained on this information launch are made as of the date of this information launch and the Firm will replace or revise publicly any of the included forward-looking statements as expressly required by relevant legislation.